Clinical Trial Update: SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial update for SHR-A1811 in a combination regimen being studied for recurrent or metastatic cervical cancer, currently in Phase 1/2 and recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• SHR-A1811

Snippet

Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Conditions: Recurrent or Metastatic Cervical Cancer | Phase 1, Phase 2 | Status: RECRUITING